What does the evidence say about Ginkgo Cognition Meta-Analysis?

The current Migaku evidence database contains 2 reusable source documents for Ginkgo Cognition Meta-Analysis. This answer focuses on benefits, uncertainty, and practical interpretation. - Significant treatment effects of 240 mg EGb 761 daily versus placebo were found for cognition ( p = 0.0467), activities of daily living ( p = 0.0230), and global clinical impression ( p = 0.0371). [Feng JX (2026); evidence level 1] - Conclusion The results of our meta-analysis of patients with mild to moderate dementia who had previously had a cerebral infarction verified by neuroimaging showed statistically significant and clinically relevant benefits of EGb 761. [Feng JX (2026); evidence level 1] - Introduction Ginkgo biloba leaf extracts belong to the most popular herbal medicines for the treatment of neurological disorders, including Alzheimer's disease (AD) or stroke. [Feng JX (2026); evidence level 1] - EGb 761, a proprietary ginkgo leaf extract, has been shown to improve brain cell energy supply, to enhance neurogenesis and neuroplasticity, to decrease blood viscosity and improve brain perfusion. [Feng JX (2026); evidence level 1] - In addition, an overview of systematic reviews synthesized the broader EGb 761 evidence base across indications and highlighted that conclusions require caution given the methodological limitations of many reviews []. [Yang YoungSoon (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.